Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Innovations for the elimination and control of visceral leishmaniasis.

Selvapandiyan A, Croft SL, Rijal S, Nakhasi HL, Ganguly NK.

PLoS Negl Trop Dis. 2019 Sep 19;13(9):e0007616. doi: 10.1371/journal.pntd.0007616. eCollection 2019 Sep. No abstract available.

2.

Development of an in vitro media perfusion model of Leishmania major macrophage infection.

O'Keeffe A, Hyndman L, McGinty S, Riezk A, Murdan S, Croft SL.

PLoS One. 2019 Jul 24;14(7):e0219985. doi: 10.1371/journal.pone.0219985. eCollection 2019.

3.

Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.

Caridha D, Vesely B, van Bocxlaer K, Arana B, Mowbray CE, Rafati S, Uliana S, Reguera R, Kreishman-Deitrick M, Sciotti R, Buffet P, Croft SL.

Int J Parasitol Drugs Drug Resist. 2019 Jun 20. pii: S2211-3207(19)30078-8. doi: 10.1016/j.ijpddr.2019.06.003. [Epub ahead of print] Review.

4.

Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis.

Wijnant GJ, Croft SL, de la Flor R, Alavijeh M, Yardley V, Braillard S, Mowbray C, Van Bocxlaer K.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00829-19. doi: 10.1128/AAC.00829-19. Print 2019 Sep.

5.

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis.

Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL.

Int J Parasitol Drugs Drug Resist. 2019 Feb 26. pii: S2211-3207(18)30185-4. doi: 10.1016/j.ijpddr.2019.02.002. [Epub ahead of print]

6.

Leishmaniasis - Authors' reply.

Burza S, Croft SL, Boelaert M.

Lancet. 2019 Mar 2;393(10174):872-873. doi: 10.1016/S0140-6736(18)33057-5. No abstract available.

PMID:
30837140
7.

Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis.

Ashwin H, Seifert K, Forrester S, Brown N, MacDonald S, James S, Lagos D, Timmis J, Mottram JC, Croft SL, Kaye PM.

Version 2. Wellcome Open Res. 2019 Jan 2 [revised 2019 Jan 1];3:135. doi: 10.12688/wellcomeopenres.14867.2. eCollection 2018.

8.

Leishmaniasis.

Burza S, Croft SL, Boelaert M.

Lancet. 2018 Sep 15;392(10151):951-970. doi: 10.1016/S0140-6736(18)31204-2. Epub 2018 Aug 17. Review.

PMID:
30126638
9.

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B.

Wijnant GJ, Van Bocxlaer K, Fortes Francisco A, Yardley V, Harris A, Alavijeh M, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00631-18. doi: 10.1128/AAC.00631-18. Print 2018 Oct.

10.

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Alavijeh M, Silva-Pedrosa R, Antunes S, Mauricio I, Murdan S, Croft SL.

Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):223-228. doi: 10.1016/j.ijpddr.2018.04.001. Epub 2018 Apr 12.

11.

Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Van Bocxlaer K, Gaukel E, Hauser D, Park SH, Schock S, Yardley V, Randolph R, Plattner JJ, Merchant T, Croft SL, Jacobs RT, Wring SA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02419-17. doi: 10.1128/AAC.02419-17. Print 2018 May.

12.

Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.

Voak AA, Standing JF, Sepúlveda N, Harris A, Croft SL, Seifert K.

J Antimicrob Chemother. 2018 May 1;73(5):1314-1323. doi: 10.1093/jac/dky014.

13.

Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02009-17. doi: 10.1128/AAC.02009-17. Print 2018 Mar.

14.

In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial.

Basilico N, Parapini S, Sparatore A, Romeo S, Misiano P, Vivas L, Yardley V, Croft SL, Habluetzel A, Lucantoni L, Renia L, Russell B, Suwanarusk R, Nosten F, Dondio G, Bigogno C, Jabes D, Taramelli D.

Molecules. 2017 Dec 1;22(12). pii: E2102. doi: 10.3390/molecules22122102.

15.

Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.

Croft SL.

Parasitology. 2018 Feb;145(2):237-247. doi: 10.1017/S0031182017001664. Epub 2017 Oct 6. Review.

16.

A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission.

Baker DA, Stewart LB, Large JM, Bowyer PW, Ansell KH, Jiménez-Díaz MB, El Bakkouri M, Birchall K, Dechering KJ, Bouloc NS, Coombs PJ, Whalley D, Harding DJ, Smiljanic-Hurley E, Wheldon MC, Walker EM, Dessens JT, Lafuente MJ, Sanz LM, Gamo FJ, Ferrer SB, Hui R, Bousema T, Angulo-Barturén I, Merritt AT, Croft SL, Gutteridge WE, Kettleborough CA, Osborne SA.

Nat Commun. 2017 Sep 5;8(1):430. doi: 10.1038/s41467-017-00572-x.

17.

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.

Voak AA, Harris A, Qaiser Z, Croft SL, Seifert K.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00497-17. doi: 10.1128/AAC.00497-17. Print 2017 Sep.

18.

Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00358-17. doi: 10.1128/AAC.00358-17. Print 2017 Aug.

19.

Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis.

Burrell-Saward H, Harris AJ, de LaFlor R, Sallam H, Alavijeh MS, Ward TH, Croft SL.

Int J Antimicrob Agents. 2017 Aug;50(2):203-209. doi: 10.1016/j.ijantimicag.2017.01.038. Epub 2017 May 25.

20.

Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesiense.

Daunes S, Yardley V, Croft SL, D'Silva C.

Bioorg Med Chem. 2017 Feb 15;25(4):1329-1340. doi: 10.1016/j.bmc.2016.12.016. Epub 2016 Dec 18.

21.

Evaluating drug resistance in visceral leishmaniasis: the challenges.

Hendrickx S, Guerin PJ, Caljon G, Croft SL, Maes L.

Parasitology. 2018 Apr;145(4):453-463. doi: 10.1017/S0031182016002031. Epub 2016 Nov 21. Review.

22.

Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.

Van Bocxlaer K, Yardley V, Murdan S, Croft SL.

J Pharm Pharmacol. 2016 Jul;68(7):862-72. doi: 10.1111/jphp.12548. Epub 2016 May 27.

23.

A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.

Tegazzini D, Díaz R, Aguilar F, Peña I, Presa JL, Yardley V, Martin JJ, Coteron JM, Croft SL, Cantizani J.

Antimicrob Agents Chemother. 2016 May 23;60(6):3524-32. doi: 10.1128/AAC.01781-15. Print 2016 Jun.

24.
25.

Drug permeation and barrier damage in Leishmania-infected mouse skin.

Van Bocxlaer K, Yardley V, Murdan S, Croft SL.

J Antimicrob Chemother. 2016 Jun;71(6):1578-85. doi: 10.1093/jac/dkw012. Epub 2016 Feb 21.

PMID:
26903275
26.

The Nobel Prize in Medicine 2015: Two drugs that changed global health.

Croft SL, Ward S.

Sci Transl Med. 2015 Dec 2;7(316):316ed14. doi: 10.1126/scitranslmed.aad5868. No abstract available.

PMID:
26631629
27.

Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.

Seifert K, Juhls C, Salguero FJ, Croft SL.

Antimicrob Agents Chemother. 2015 Sep;59(9):5819-23. doi: 10.1128/AAC.00273-15. Epub 2015 Jun 8.

28.

Chemical and bioassay techniques to authenticate quality of the anti-leishmanial drug miltefosine.

Kaur H, Seifert K, Hawkes GE, Coumbarides GS, Alvar J, Croft SL.

Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):31-38. doi: 10.4269/ajtmh.14-0586. Epub 2015 Apr 20.

29.

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.

Riede O, Seifert K, Oswald D, Endmann A, Hock C, Winkler A, Salguero FJ, Schroff M, Croft SL, Juhls C.

Gene Ther. 2015 Aug;22(8):628-35. doi: 10.1038/gt.2015.35. Epub 2015 Apr 30.

30.

A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis.

Burrell-Saward H, Rodgers J, Bradley B, Croft SL, Ward TH.

J Antimicrob Chemother. 2015 Feb;70(2):510-7. doi: 10.1093/jac/dku393. Epub 2014 Oct 8.

31.

Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.

Das S, Freier A, Boussoffara T, Das S, Oswald D, Losch FO, Selka M, Sacerdoti-Sierra N, Schönian G, Wiesmüller KH, Seifert K, Schroff M, Juhls C, Jaffe CL, Roy S, Das P, Louzir H, Croft SL, Modabber F, Walden P.

Sci Transl Med. 2014 Apr 30;6(234):234ra56. doi: 10.1126/scitranslmed.3008222.

32.

Activity of anti-cancer protein kinase inhibitors against Leishmania spp.

Sanderson L, Yardley V, Croft SL.

J Antimicrob Chemother. 2014 Jul;69(7):1888-91. doi: 10.1093/jac/dku069. Epub 2014 Mar 25.

PMID:
24668412
33.

Emerging paradigms in anti-infective drug design.

Barrett MP, Croft SL.

Parasitology. 2014 Jan;141(1):1-7. doi: 10.1017/S0031182013001224.

34.

Highly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferase.

McLatchie AP, Burrell-Saward H, Myburgh E, Lewis MD, Ward TH, Mottram JC, Croft SL, Kelly JM, Taylor MC.

PLoS Negl Trop Dis. 2013 Nov 21;7(11):e2571. doi: 10.1371/journal.pntd.0002571. eCollection 2013 Nov.

35.

Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex.

Mohamed-Ahmed AH, Seifert K, Yardley V, Burrell-Saward H, Brocchini S, Croft SL.

Antimicrob Agents Chemother. 2013 Oct;57(10):4608-14. doi: 10.1128/AAC.02343-12. Epub 2013 Jun 24.

36.

Case study for a vaccine against leishmaniasis.

Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG.

Vaccine. 2013 Apr 18;31 Suppl 2:B244-9. doi: 10.1016/j.vaccine.2012.11.080. Review.

PMID:
23598489
37.

Noncovalent complexation of amphotericin-B with Poly(α-glutamic acid).

Mohamed-Ahmed AH, Les KA, Seifert K, Croft SL, Brocchini S.

Mol Pharm. 2013 Mar 4;10(3):940-50. doi: 10.1021/mp300339p. Epub 2013 Feb 8.

PMID:
23234235
38.

Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis.

Mohamed-Ahmed AH, Brocchini S, Croft SL.

Curr Opin Infect Dis. 2012 Dec;25(6):695-702. doi: 10.1097/QCO.0b013e328359eff2. Review.

PMID:
23147810
39.

Management of trypanosomiasis and leishmaniasis.

Barrett MP, Croft SL.

Br Med Bull. 2012;104:175-96. doi: 10.1093/bmb/lds031. Epub 2012 Nov 7. Review.

40.

Review of pyronaridine anti-malarial properties and product characteristics.

Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, Borghini-Fuhrer I, Rim HJ.

Malar J. 2012 Aug 9;11:270. doi: 10.1186/1475-2875-11-270.

41.

Leishmaniasis chemotherapy--challenges and opportunities.

Croft SL, Olliaro P.

Clin Microbiol Infect. 2011 Oct;17(10):1478-83. doi: 10.1111/j.1469-0691.2011.03630.x. Review.

42.

Developing novel strategies to prevent parasitic infections.

Staines HM, Croft SL, Horrocks PD.

Expert Rev Anti Infect Ther. 2011 Jul;9(7):783-5. doi: 10.1586/eri.11.62.

PMID:
21810050
43.

In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani.

Seifert K, Munday J, Syeda T, Croft SL.

J Antimicrob Chemother. 2011 Apr;66(4):850-4. doi: 10.1093/jac/dkq542. Epub 2011 Feb 3.

PMID:
21393188
44.

Triclosan is minimally effective in rodent malaria models.

Baschong W, Wittlin S, Inglis KA, Fairlamb AH, Croft SL, Kumar TR, Fidock DA, Brun R.

Nat Med. 2011 Jan;17(1):33-4; author reply 34-5. doi: 10.1038/nm0111-33. No abstract available.

PMID:
21217674
45.

Antiprotozoal activity of drimane and coloratane sesquiterpenes towards Trypanosoma brucei rhodesiense and Plasmodium falciparum in vitro.

Wube AA, Bucar F, Gibbons S, Asres K, Rattray L, Croft SL.

Phytother Res. 2010 Oct;24(10):1468-72. doi: 10.1002/ptr.3126.

PMID:
20878696
46.

Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine.

Yardley V, Gamarro F, Croft SL.

Antimicrob Agents Chemother. 2010 Dec;54(12):5356-8. doi: 10.1128/AAC.00985-10. Epub 2010 Sep 13. Erratum in: Antimicrob Agents Chemother. 2011 Jan;55(1):458.

47.

Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas.

Dujardin JC, González-Pacanowska D, Croft SL, Olesen OF, Späth GF.

Trends Parasitol. 2010 Aug;26(8):395-403. doi: 10.1016/j.pt.2010.04.012. Epub 2010 Jun 9. Review.

PMID:
20538522
48.

In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole.

Luna KP, Hernández IP, Rueda CM, Zorro MM, Croft SL, Escobar P.

Biomedica. 2009 Sep;29(3):448-55.

PMID:
20436996
49.

In vitro and in vivo evaluation of self-microemulsifying drug delivery system of buparvaquone.

Venkatesh G, Majid MI, Mansor SM, Nair NK, Croft SL, Navaratnam V.

Drug Dev Ind Pharm. 2010 Jun;36(6):735-45. doi: 10.3109/03639040903460446.

PMID:
20136493
50.

In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.

Seifert K, Escobar P, Croft SL.

J Antimicrob Chemother. 2010 Mar;65(3):508-11. doi: 10.1093/jac/dkp500. Epub 2010 Jan 20.

PMID:
20089542

Supplemental Content

Loading ...
Support Center